Dare Bioscience, Inc. (NASDAQ:DARE) a clinical-stage, women biopharmaceutical company, is expected to report second quarter earnings results, after market close, on Wednesday 12th August 2020.
Analysts polled by Thomson Reuters anticipate second quarter loss of $ 0.15 per share from revenue of $ 0.21 million.
Looking ahead, the full year loss are expected at $ 0.63 per share on the revenues of $ 0.62 million.
Previous Quarter Performance
Dare Bioscience, Inc. recorded loss for the first quarter of $ 0.18 per share, from the revenue of . The quarterly earnings compared with the same quarter last year. The consensus estimates are loss of $ 0.29 per share The bottom line results beat street analysts by $ 0.11 or 37.93 percent, at the same time, top line results analysts by $ 100.20 million or .
wpDataChart with provided ID not found! wpDataTable with provided ID not found!Stock Performance
According to the previous trading day, closing price of DARE was $ 1.19, representing a 72.46 % increase from the 52 week low of $ 0.69 and a 46.4 % decrease over the 52 week high of $ 2.22.
The company has a market capital of $ 31.71 million and is part of the Healthcare sector and Biotechnology industry.
[stock_market_widget type=”chart” template=”basic” color=”orange” assets=”DARE” range=”1y” interval=”1mo” axes=”true” cursor=”true” api=”yf” style=”height: 400px;”]
Conference Call
Dare Bioscience, Inc. will be hosting a conference call at 4:30 PM eastern time on 12th August 2020, to discuss its 2Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.darebioscience.com
Daré Bioscience, Inc., a clinical-stage biopharmaceutical company, focuses on developing and marketing womens reproductive health products in the United States. The company intends to develop therapies in the areas of contraception, vaginal health, sexual health, and fertility. Its product portfolio includes Ovaprene, a non-hormonal monthly contraceptive vaginal ring; Sildenafil Cream, a novel cream formulation of sildenafil to treat female sexual arousal disorder utilizing the active ingredient in Viagra; DARE-BV1, a hydrogel formulation of clindamycin phosphate 2% to treat bacterial vaginosis via a single application; and DARE-HRT1, a combination of bio-identical estradiol and progesterone intravaginal ring for hormone replacement therapy.
